Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination among US adults aged 18–49 years at increased risk for severe RSV disease
Randomized trial evaluates cost-effectiveness and public health benefits of RSVPreF3 vaccination in at-risk adults, suggesting notable advantages.
Key Points
This study aims to assess the public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination among US adults at increased risk for severe RSV disease.
Employed a static, multicohort Markov model to simulate outcomes over 5 years.
Included a base-case population of adults aged 18–49 years with various risk factors for severe RSV disease.
Conducted sensitivity and scenario analyses to evaluate model robustness and uncertainty.
Estimated that 7,957,333 out of 24,260,162 increased-risk adults received vaccination, preventing 869,819 RSV cases.
Predicted 20,540 QALY losses and 444 RSV-related deaths avoided; ICER was $61,717 per QALY gained.
Vaccination was cost-saving or cost-effective in all condition-specific subgroups based on a $150,000/QALY threshold.